Recoil Therapeutics develops injectable synthetic biomaterial scaffolds that replace degraded extracellular matrix fibers and restore mechanical integrity in aging tissues. The in‑situ gelation platform mimics collagen and elastin mechanics, enabling localized regeneration for skin, cartilage, and intervertebral disc applications.
Funding
Funding not disclosed
Founders
Product
Problem
Age-related tissue degeneration is driven by the breakdown of extracellular matrix (ECM) fibers such as collagen and elastin, leading to loss of mechanical integrity and functional decline in skin, cartilage, and intervertebral discs.
Solution
Recoil Therapeutics creates injectable, non‑biological biomaterial scaffolds that replace degraded ECM fibers and restore the tissue’s mechanical architecture. By engineering novel chemistries that form a supportive scaffold in situ, the platform reestablishes the physical microenvironment required for cellular function. The approach targets the root cause of tissue aging rather than merely addressing symptoms, enabling localized treatment with reduced systemic risk. Initial development focuses on skin regeneration, with a roadmap to extend the technology to joint cartilage and intervertebral disc degeneration.
Target Audience
Primary customers are dermatology and aesthetic clinics seeking regenerative skin treatments, as well as orthopedic and spine specialists interested in minimally invasive solutions for cartilage and disc degeneration.
Features
- Injectable scaffold formulation that can be delivered locally to target tissues
- Non‑biological, synthetic polymer network designed to mimic collagen and elastin mechanics
- Engineered chemistry that enables in‑situ gelation and integration with native ECM
- Platform scalability to address multiple tissue types (skin, cartilage, intervertebral disc)
- Mechanism‑driven design focused on restoring structural integrity rather than temporary filling